ICU for Pneumonia in Elderly Ups Survival, Not Costs

This article originally appeared here.
Share this content:
ICU for Pneumonia in Elderly Ups Survival, Not Costs
ICU for Pneumonia in Elderly Ups Survival, Not Costs

WEDNESDAY, Sept. 23, 2015 (HealthDay News) -- Admitting older, low-risk patients with pneumonia to the intensive care unit (ICU) -- compared with admission to regular wards -- is linked with higher survival rates but not higher medical expenses, new research suggests. The study was published in the Sept. 22/29 issue of the Journal of the American Medical Association.

Researchers led by Thomas Valley, M.D., of the University of Michigan in Ann Arbor, analyzed the link between ICU admissions and outcomes among older people hospitalized for pneumonia as well as 30-day death rates and overall medical costs. The study included more than one million Medicare beneficiaries older than age 64 who were admitted to 2,988 U.S. hospitals for pneumonia from 2010 to 2012. Of those, 30 percent were admitted to the ICU. Meanwhile, 36 percent of those living within <3.3 miles of the hospital were admitted to the ICU compared to 23 percent of those who lived farther away.

Of the 13 percent of patients whose admission appeared to be dependent only on distance, survival rates were higher among those treated in the ICU than in general wards. The researchers pointed out that Medicare spending and hospital costs were comparable.

The findings argue against efforts to reduce ICU admissions, at least for older patients with pneumonia, Ian Barbash, M.D., and Jeremy Kahn, M.D., of the University of Pittsburgh School of Medicine, note in an accompanying editorial. "The greatest lesson from this study may be that low-value health care is difficult to find," they write. "Reducing health care spending by preventing ICU readmissions will require addressing the difficult questions about rationing ICU care and the degree to which the nation can afford to make intensive care available to anyone at any time."

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths